RTW Venture Fund Limited
RTWG.L
London Stock Exchange116.63
GBp
+0.63
(+0.55%)
RTW Venture Fund Limited
RTWG.L
(London Stock Exchange)
Recent
price
116.63
P/E
ratio
-6.86
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- RTW Venture Fund Limited RTW Venture Fund Limited (ticker: RTWG.L), also known as RTW Biotech Opportunities Ltd following its name change in June 2023, operates as a Guernsey-based closed-end investment fund that specializes in identifying and investing in transformative assets with high growth potential across the life sciences, biopharmaceutical, and medical technology sectors. The fund, managed by RTW Investments LP headquartered in New York with additional offices in London and Shanghai, focuses on a full lifecycle approach, providing capital and expertise to companies from early-stage venture creation through pre-IPO clinical development to public market investments; its core offerings include direct equity investments in innovative biotechs developing next-generation therapies and technologies aimed at significantly improving patient outcomes, such as genetic targets, molecular therapeutics, cardiovascular medicines, and presbyopia-correcting eye drops. Geographically, the fund maintains a global reach with approximately 80% of its portfolio allocated to U.S.-based assets originating from labs in the US, UK, Europe, and Asia, while targeting clinical-stage and growth-oriented companies serving healthcare markets worldwide. In recent developments, the fund participates actively in portfolio company milestones, including Merck's $10 billion acquisition of Verona Pharma, a position held by the fund, as well as Novartis's acquisition of Avidity Biosciences and Biogen's acquisition of Alcyone Therapeutics in 2025, which highlight ongoing merger and acquisition activity enhancing shareholder value. RTW Biotech Opportunities advances its capital allocation strategy through the completed $57.1 million acquisition of a 25.5% stake in Arix Bioscience in early 2025, positioning it to support the Arix scheme at the forthcoming AGM and potentially acquire additional assets. Further, the fund engages in significant financings, such as participations in Ventyx Biosciences' $114 million round and Visus Therapeutics' $36 million round in 2023, alongside a $25 million private placement in Milestone Pharmaceuticals, while portfolio company Kailera Therapeutics announces positive Phase 2 data for its GLP-1/GIP dual agonist HRS9531 in obesity treatment in January 2025; these activities underscore a long-term investment horizon driven by deep scientific expertise and opportunistic transactions.